Treatment of human monocytes with vascular endothelial growth factor (VEGF) isolated from tumor cell supernatants was reported t o induce monocyte activation and migration. In this study we show that recombinant human VEGFle6 and VEGF, , , had a maximal effect on human monocyte migration at 65 t o 250 pmol/L. Chemotactic activity of VEGF, , , was inhibited by a specific antiserum against VEGF, by heat treatment of VEGFle6, and by protein kinase inhibitors. In addition, we could show that VEGF-stimulated monocyte migration is mediated by a pertussis toxin-sensitive GTP-binding protein. Placenta growth factor (PIGFIU), a heparin-binding growth factor related t o VEGF, was also chemotactic for monocytes at concentrations between 2.5 and 25 pmol/L. In accordance with these findings, human monocytes showed ECRUITMENT OF mononuclear phagocytes from the R blood compartment into tissues is a crucial process in inflammatory reactions and immune response. Monocyte extravasation involves interaction with the vascular endothelium and response to tissue-and/or vessel wall-derived molecules. The identification of adhesion molecules, whose expression is upregulated on endothelial cells, and of novel cytokines has considerably improved the understanding of factors involved in the regulation of monocyte migration, localization, and activation in tissues.
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Vascular endothelial growth factor (VEGF) is a mitogen specific for endothelial cells. VEGF has been discovered in and purified from media conditioned by several tumor cell lines and bovine pituitary folliculo-stellate cells. Molecular cloning of the cDNA suggests that in human cells at least four species of VEGF can occur as 121, 165, 189, and 206 amino acid forms, generated by alternative splicing (for a review, see Senger et all). It has been shown that VEGFlhS induces monocyte activation manifested by the induction of tissue factor and monocyte chemotaxis.' Another growth factor, related to the VEGF family, is the recently identified placenta growth factor (PIGF), of which two forms, PIGF,,, and P1GFIs2, are known so far. The overall homology between the amino acid sequences of P1GFlS2 and VEGF189 is about 40%, but, if the conservative amino acid changes are considered, the sequence homology increases to about 67%. Like VEGF, PlGF is a secreted, dimeric, and N-glycosylated pr~tein.'.~ Because of the structural and biochemical similarities between VEGF and PlGF, it was suggested that the latter might also be an angiogenic f a~t o r .~ However, the physiologic functions of PlGF are almost completely unknown. High-affinity binding sites for VEGF were mainly found on endothelial c e k In this study, we have investigated the chemotactic properties of VEGFlhSr VEGFlzl, and PlGFls2 on human monocytes and found that all three growth factors induce migration in a dose-dependent manner. Moreover, we show, for the first time, that the VEGF-induced chemotactic response on human monocytes is mediated via the VEGF-receptor flt-1.
MATERIALS AND METHODS
Reagents. Human recombinant VEGF,6s, VEGF,,,, and PIGFls2 were expressed in the baculovirus system, purified, and tested for biologic activity as described.'.l5 fMLP was from Sigma Chemical Co (St Louis, MO). C-I was a kind gift from Dr C.E. McCall (Bowman Gray School of Medicine, Winston-Salem, NC). Genistein and pertussis toxin (PTox) were from Calbiochem (San Diego, CA). Bacterial lipopolysaccharid (LPS D,, Escherichia coli 055:B5) was from Difco Labs (Detroit, MI).
Primary human umbilical vein endothelial cells (HU-VEC) were purchased from Promocell (Heidelberg, Germany) and cultured according to the provided protocol. Human smooth muscle cells were isolated and cultured as described."
Peripheral blood mononuclear cells (PBMC) were obtained from buffy coats of blood from normal donors courtesy of the Transfu-
Cell lines.
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Blood, , 25 mmol/L HEPES, 1 mg/mL bovine serum albumin, pH 7.4) at a density of 2.5 to 6 X IO6 cells/ mL. One hundred microliters of the cell suspension was plated on a 48-well culture disk (with flat bottom). After adding the labeled and unlabeled VEGF165r the final volume was 200 pL per well. The binding was performed for 3 hours on ice with increasing concentrations of 'Z51-VEGF165.1' Unspecific binding was determined for each concentration by the addition of a 100-fold excess of unlabeled ligand. For competition assays, the cells were incubated with a constant concentration of 1251-VEGF165 (20 ng/mL) and increasing amounts of purified recombinant human VEGF or PlGF. Cells were washed extensively with binding buffer and then solubilized with 0.3 m o m NaOH, 0.1% sodium dodecyl sulfate (SDS). Radioactivity present in the lysates was quantified using a gamma counter (Beckmann, Munchen, Germany). Recombinant human VEGF165 was iodinated to 30,000 to 136,000 cpm/ng using the chloramin T method."
Total RNA was prepared from cells and human placental tissue by a guanidinekaesium chloride centrifugation method'" or by a modification of the acid guanidine thiocyanatephenol-chloroform extraction protocol." Northern blot analysis was performed as described." For the flt-1 gene, hybridization was performed with a 1.05-kb cDNA fragment corresponding to a part of the extracellular domain (nucleotide 172-1231) of the human cDNA ~equence.~." For KDR, hybridization was performed with a 1.4-kb cDNA fragment corresponding to a part of the extracellular domain (nucleotide 360-1720) of the human cDNA sequence? For FLT-4, hybridization was performed with a 1.2-kb cDNA fragment that covers the transmembrane part, the full kinase domain, and a part of the C-terminus (nucleotide 2534-3788).14
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Chemotactic properties of VEGFIGs, VEGFI2], and
A first series of experiments was designed to charP1GFlS2. acterize the chemotactic properties of VEGF165. Table 1 shows that VEGF165 was able to induce migration of monocytes across polycarbonate filters in a dose-dependent manner. The maximal response was obtained at a concentration of 220 pmoVL. At this concentration, the number of migrated monocytes was about 65% of that observed with an optimal concentration of fMLP (10 nmoVL) that was used as a reference chemoattractant, active on all leukocyte populations. Table 1 also shows that, under similar experimental conditions, VEGF165 was able to induce migration of PMN. The dose-response curve obtained with PMN was sharper than that observed with monocytes, although maximal migration was obtained at the same concentration. At 220 pmoVL VEGF165, PMN migration was about 45% of the response observed in the presence of 10 nmoVL fLMP. Heat-inactivated VEGF165, as well as VEGF165 preadsorbed on Sepharose-protein G beads coated with anti-VEGF antiserum, were inactive ( Fig 1A) . These results indicate that vEGF165 is able to elicit a migratory response in human monocytes and PMN.
To clarify whether the migration of monocytes across filters depends on the presence of a VEGF165 gradient between the lower and the upper compartment, we performed checkerboard experiments using polycarbonate filters with the number of migrated cells as the end point. As shown in Table 2 , maximal induction of migration occurred in the presence of a positive concentration gradient between the two compartments (higher concentration below the filter). In the presence of equal concentrations of VEGF,,, above and below the filter or of a negative gradient (higher concentration above the filter), no enhanced migration occurred. These results indicate that VEGF165 is able to activate a chemotactic response in human monocytes with no appreciable chemokinetic activity.
The mechanism(s) involved in the induction of monocyte chemotaxis after VEGF165 stimulation is unknown. The involvement of protein kinases was investigated by using inhibitors. Figure 1B shows that both C-I and genistein, inhibitors of threoninelserine kinases and tyrosine kinases, respectively, cause a dose-dependent inhibition of monocyte Different concentrations of VEGF,= (in nanograms per milliliter) were supplied to the upper and/or lower compartment of the chemo- of phorbol 12-myristate 13-acetate (PMA) was unaffected. This result suggests that the VEGF-induced migration of human monocytes is mediated via a pertussis toxin-sensitive GTP-binding protein.
We further compared the chemotactic properties of VEGFIZl and of the VEGF-related growth factor P1GFjS2 with those of VEGF165 described above. Table 3 shows that VEGF,,, as well as P1GF152 were able to induce migration of monocytes. The maximal response to VEGF,,, was observed at 65 pmol/L and to P1GF152 at 7 pmoVL. At these concentrations, the percentage of migrated monocytes was about 50% for VEGF,,, and about 40% for P1GF152 of that observed at 10 nmol/L d M P . Although the maximal effects to VEGFIzI and P1GF152 were observed at lower concentrations as compared with VEGF165 (65 pmol/L and 7 pmol/L, respectively, as compared with 220 pmol/L), both factors had a lower efficacy than VEGF165 in that they induced the migration of less cells.
Expression of VEGF receptors in human monocytes. The presence of specific binding sites for '*'I-VEGFlh5 on human monocytes was investigated. In six different experiments we observed specific binding of VEGF165 in the range of 60% to 80% of total binding (Fig 3) . Half-maximal binding occured at 1 to 1.5 nmol/L, which is 20-to 25-fold lower than that observed for endothelial cells and threefold to fivefold lower than that observed on human monocytes by Shen et al.h Because VEGF binds to and induces migration of monocytes, it was of interest which of the two known VEGF receptors is involved. Therefore, we performed Northern blot analysis of total RNA from human monocytes and PMNs using human cDNA sequences appropriate for the two VEGF receptors flt-1 and KDR as well as for the related receptor, FLT-4. The result is shown in different from that obtained with placental tissue and with HUVECs." Three mRNA species of 7.5, 3.4, and 2.7 kb, similar to those from placenta, could be detected. However, in contrast to human placental tissue, in which the 3.4-kb mRNA species is the dominant one, in monocytes the 2.7-kb and 7.5-kb transcripts are the dominant mRNA species, with a similar expression level. The 2.7-kb mRNA transcript is too short to code for the full-length receptor mRNA and probably encodes a truncated form of flt-l.26 Similar to monocytes, PMNs also express only the gene for the flt-1 receptor type, but the expression is much weaker than that observed in monocytes. PMNs show flt-1 transcripts of 7.5 kb and 2.7 kb but lack the 3.4-kb mRNA species (Fig 4) .
PlCF is believed to act via the VEGF receptor flt-1. It has been shown that PlGF binds to flt-127.28 and competes with VEGF binding to flt-l",28 (Barleon and Martiny-Baron, unpublished data). We performed competition experiments with 1251-VEGF16s and P1GFIs2 on human monocytes. Figure  5 shows the results. P1GF152 is able to compete for the binding of 1251-VEGF165 with a similar efficiency as unlabeled VEGF16s . Taken together, these data indicate that the VEGF receptor flt-1 is expressed in human monocytes and PMNs and that both VEGF and PlGF bind to this receptor. Thus, it is likely that both factors induce the chemotactic response by activating the VEGF receptor flt-1.
To investigate whether flt-1 gene expression in human monocytes is upregulated by LPS, a prototypic monocyte activator:' monocytes were exposed to 100 ng/mL LPS for 2 to 4 hours. Figure 6 shows that flt-1 transcripts increase after just 2 hours of stimulation; this stimulation was dose dependent (data not shown). In preliminary experiments, we observed that 16 hours of incubation of monocytes with 100 nglmL LPS resulted in a 1.5-fold to twofold increase in specific binding of L251-VEGF165 as compared with untreated cells. The calculated half-maximal binding was 0.4 to 0.6 nmol/L for LPS-treated and 1 to 1.5 nmoVL for untreated monocytes. In addition, LPS-incubated monocytes showed an increased ability to migrate in response to suboptimal concentrations of VEGF165 (data not shown).
Taken together, our results indicate that, in human monocytes, the migration signal induced by VEGF and most prob- For ably also that induced by PIGFIs2 is mediated via the flt-l receptor and, secondly, activation of human monocytes by LPS causes a significant upregulation of the flt-1 mRNA level and an increase of specific binding for VEGF. Factor (fold-excess) otal role in modulating the repair process. Although the role of macrophages in wound repair is certainly multi-functional, several lines of evidence show that they are key regulators of new capillary growth or angiogenesis.'"," Previous studies have shown that VEGF165 induces directed migration of mononuclear phagocytes across an endothelial cell monolayer as well as their activation based on expression of tissue factor procoagulant activity.'.' For VEGFlh5, we observed a maximal response in migration of human monocytes at 220 pmol/L, which is in the same range as reported by Clauss et al' and Shen et a1. 6 Checkerboard experiments with VEGFI6.( clearly showed that the migration depends on the presence of a VEGFlhs gradient. VEGFlos also induced a chemotactic response in PMNs but seems to be less active on these cells. PMNs are another nonspecific inflammatory cell type attracted in the early phase of an acute inflammatory process. These results indicate that VEGF is able to act on the two main cell types seen in inflammatory responses. The mechanism(s) involved in the migratory response of leukocytes is not well understood. The current view of chemoattractant signalling indicates a substantial diversity in the structural elements and pathways involved." Shen et a16 showed that VEGFlh5, like most of the known monocyte chemotactic factors, induces a transient increase in cytosolic Ca", which peaks at 30 seconds. In the present study, we show that, as with other chemotactic agonists," the signal transduction pathway of VEGF16s in human monocytes involves both threoninekerine as well as tyrosine kinases. Inhibitors of both types of kinases exhibit a dosedependent attenuation of monocyte migration. It was recently shown that PTox inhibits the bFGF-induced chemotactic response in bovine aortic endothelial cells, whereas the bFGF-induced mitogenic response was unaffected.*' This result shows that distinct intracellular signalling mechanisms are involved in the migratory and proliferative responses of endothelial cells to bFGF and that the migratory signal is mediated by a pertussis toxin-sensitive GTP-binding protein. to receptors containing seven transmembrane regions, eg, the rhodopsin and adrenergic receptors3' However, recent evidence has indicated that other types of receptors. such as the insulin."' epidermal growth factor.'5 and the transforming growth factor fl I '" receptors, are also coupled to pertussis toxin-sensitive. 40-to 4 I -kD Gi-like G-proteins. In preliminary experiments, we could show that this is also the case for the VEGF receptor flt-I , at least in monocytes. The VEGFlhSinduced chemotactic response was inhibited in a dose-dependent manner by PTox. We are currently investigating whether the VEGF-induced migratory response in vascular endothelial cells is also blocked by PTox.
The biologic functions of PlGF are still unclear. It has been shown by some investigators that PlGF induces a mitogenic response in endothelial cells.',J This could not be confirmed by others'7 (Barleon, unpublished data). It was recently suggested that PlGF could amplify the action of VEGF by displacing it from flt-l binding sites and thus promoting binding to KDR." On the other hand, it was shown that PIGF,,, and PIGF15? induce a chemotactic response in HUVECs with similar potency as VEGF1(,,." We show here that PIGFIS2 induces human monocyte migration across polycarbonate filters in a dose-dependent manner. The maximal response occured at concentrations somewhat lower than those obtained with VEGF,,, (7 p m o l n for P1GF152 and 220 pmol/L for VEGF16,). However, the efficacy of PlGF appears to be lower, inducing migration of less cells. These results and those obtained by Weindel et aIJ7 show that PlGF is able to induce a chemotactic response in human monocytes as well as in endothelial cells, indicating clearly a direct biologic activity of the PlGF protein.
The next question we addressed was which of the two known VEGF receptors, KDR or flt-I, is responsible for VEGF-induced activation of human monocytes and PMNs. Northern blot analysis showed that both cell types express only the gene for the flt-l receptor type but not for KDR. This is in marked contrast to human vascular endothelial cells, in which transcripts for both receptor types could be detected." We suggest that the VEGF-and most probably also the PIGF-induced migration of human monocytes is mediated via the VEGF receptor flt-1. This is supported by the following findings. ( I ) PIGFlll and PIGFls2 bind with high affinity to the flt-l receptor but not to the KDR receptor t y~e '~. '~ (Barleon and Martiny-Baron, unpublished data). (2) PIGFlzz is able to compete for "51-VEGF16s binding to human monocytes. (3) There exists only one high-affinity binding site for VEGFlh5 on human monocytes.h These results clearly indicate that the migration signal of VEGF and most probably of PIGFls2 is mediated via the flt-l receptor in human monocytes. However, the existence of another yet unidentified receptor for VEGF and/or PlGF in these cells cannot be excluded.
There is unequivocal evidence that the KDR receptor type is a signal transducing molecule mediating a mitogenic response,"'.'' whereas the function of the flt-I receptor type remains unclear."." Transfected porcine aortic endothelial cells (PAEC)." CHO cells, and NIH3T3 cellsX~"' expressing flt-l do not show any mitogenic response upon exposure to VEGF. In contrast, transfection of PAECs with human KDR cDNA or transfection of NIH3T3 with the mouse homolog flk-I cDNA resulted in VEGF-induced receptor autophosphorylation and a mitogenic
The results presented here show for the first time that, in human monocytes, flt-l mediates the chemotactic response upon activation by VEGF and PIGF, showing a function for the flt-l receptor.
Because corneal endothelial cells (BCECs) also express the flt-l receptor type and respond to VEGF with chemotaxis,''" it is suggested that the flt-l receptor might be responsible for mediating the chemotactic signal in some cells (eg, BCECs, monocytes, and PMN). whereas the KDR receptor type may be responsible for the mitogenic and chemotactic response in vascular endothelial cells. However, additional studies are needed to support this hypothesis.
Another interesting point is the significant upregulation of the flt-l mRNA level by LPS. a prototypic monocyte activator.'" Whether this increase in flt-1 transcripts is due to a higher transcription rilte or to an increase in flt-1 mRNA stability is not yet known. In preliminary experiments, we found that the upregulation of the flt-I mRNA level by LPS seems also to result in an increase in the specific binding of 1'51-VEGF16s to human monocytes and in a potentiated chemotactic response. 
